| 1 |
33070465 | AMP-activated protein kinase activation primes cytoplasmic translocation and autophagic degradation of the BCR-ABL protein in CML cells. | 2021 Jan |
1 |
| 2 |
32305283 | Arsenic trioxide-induced p38 MAPK and Akt mediated MCL1 downregulation causes apoptosis of BCR-ABL1-positive leukemia cells. | 2020 Apr 17 |
5 |
| 3 |
24129092 | VEGF depletion enhances bcr-abl-specific sensitivity of arsenic trioxide in chronic myelogenous leukemia. | 2013 Nov |
3 |
| 4 |
22330069 | Inhibition of small GTPase RalA regulates growth and arsenic-induced apoptosis in chronic myeloid leukemia (CML) cells. | 2012 Jun |
1 |
| 5 |
22898604 | Autophagic degradation of the BCR-ABL oncoprotein and generation of antileukemic responses by arsenic trioxide. | 2012 Oct 25 |
1 |
| 6 |
23100300 | BCR-ABL/p62/SQSTM1: a cannibal embrace. | 2012 Oct 25 |
2 |
| 7 |
21570118 | AID expression is correlated with Bcr-Abl expression in CML-LBC and can be down-regulated by As2O3 and/or imatinib. | 2011 Oct |
1 |
| 8 |
19563028 | [Arsenic trioxide inhibits cell growth in imatinib-resistant bcr-abl mutant cell lines in vitro]. | 2009 Jan |
6 |
| 9 |
17495969 | Arsenic trioxide and proteasome inhibitor bortezomib synergistically induce apoptosis in leukemic cells: the role of protein kinase Cdelta. | 2007 Jul |
2 |
| 10 |
17550858 | Enhanced Bcr-Abl-specific antileukemic activity of arsenic trioxide (Trisenox) through glutathione-depletion in imatinib-resistant cells. | 2007 Jun |
4 |
| 11 |
17121903 | Arsenic trioxide affects signal transducer and activator of transcription proteins through alteration of protein tyrosine kinase phosphorylation. | 2006 Nov 15 |
1 |
| 12 |
17121928 | Activation of mammalian target of rapamycin and the p70 S6 kinase by arsenic trioxide in BCR-ABL-expressing cells. | 2006 Nov |
1 |
| 13 |
14534537 | Leukemia-associated translocation products able to activate RAS modify PML and render cells sensitive to arsenic-induced apoptosis. | 2003 Oct 9 |
1 |
| 14 |
14633726 | Arsenic trioxide inhibits translation of mRNA of bcr-abl, resulting in attenuation of Bcr-Abl levels and apoptosis of human leukemia cells. | 2003 Nov 15 |
4 |
| 15 |
12135670 | In vitro studies of the combination of imatinib mesylate (Gleevec) and arsenic trioxide (Trisenox) in chronic myelogenous leukemia. | 2002 Jul |
4 |
| 16 |
12476305 | Novel targeted therapies for Bcr-Abl positive acute leukemias: beyond STI571. | 2002 Dec 9 |
1 |
| 17 |
11368438 | Co-treatment with As2O3 enhances selective cytotoxic effects of STI-571 against Brc-Abl-positive acute leukemia cells. | 2001 May |
6 |
| 18 |
10910048 | BCR-ABL mediates arsenic trioxide-induced apoptosis independently of its aberrant kinase activity. | 2000 Jul 1 |
7 |
| 19 |
11721366 | [Effects of As2O3 on the BCR/ABL protein tyrosine phosphorylation in K562 cells]. | 1999 Dec |
5 |
| 20 |
11243118 | [Protein tyrosine kinase (PTK) activities during the induction of apoptosis by arsenic trioxide (As2O3)]. | 1998 May |
3 |